During his career, Dr. Kang contributed innovative ideas to individuals who have Central Nervous System (CNS) disease.
IRVINE, CA, March 11, 2024 /24-7PressRelease/ — Namin Kang, PhD, has been selected for inclusion in Marquis Who’s Who. As in all Marquis Who’s Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Dr. Kang currently serves as the associate director of drug substance at Otsuka Pharmaceutical Companies (U.S.), a role he has held since 2018. In this capacity, he oversees the research and development processes to ensure they operate efficiently. Dr. Kang also manages the manufacturing of drug substances for clinical trials and oversees drug manufacturing facilities worldwide. Moreover, he leads and manages drug substance manufacturing activities to ensure the highest purity in drug development for clinical trials. Dr. Kang’s leadership and expertise have been instrumental in advancing the company’s pharmaceutical innovations.
With locations in California, Maryland, and New Jersey, Otsuka Pharmaceutical Companies is a health care company dedicated to creating new products for better health worldwide. The organization focuses on three specific categories: neuroscience, nephrology, and digital innovation.
Before his current position, Dr. Kang was a senior scientist at Moravek Biochemicals Inc. from 2017 to 2018, where he contributed to developing biochemical compounds. Between 2015 and 2016, he served as a research and development manager at Aspira Scientific, focusing on synthesizing new chemical entities. He also garnered success as a senior chemist at Edwards Lifesciences from 2013 to 2015, where he was involved in working on life-saving medical devices. Earlier in his career, Dr. Kang was affiliated with Ricera Biosciences, hired as a synthetic organic chemist in 2008 before being promoted to a scientist from 2011 to 2013. He also worked at American Radiolabeled Chemicals in 2008 as a scientist and at KOSEF as a research scientist, dating to 2000.
During his career, Dr. Kang contributed innovative ideas to individuals who have Central Nervous System (CNS) disease. Looking toward the future, he has set his sights on future goals within the pharmaceutical industry. Among these plans, Dr. Kang has become deeply engaged in developing advanced pharmaceuticals currently in late-stage clinical trials with aspirations of bringing them to the market.
In preparation for his distinguished career in the sciences, Dr. Kang received a Bachelor of Science in chemistry from Kosin University in 1998, Master of Science in polymer chemistry from Pusan National University in 2000 and a Doctorate of Philosophy in synthetic, organic, and medicinal chemistry from the Florida Institute of Technology in 2007.
Remaining aware of developments in his field, Dr. Kang is active as a professional member of the American Chemical Society.
About Marquis Who’s Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who’s Who in America®, Marquis Who’s Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Marquis celebrates its 125th anniversary in 2023, and Who’s Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who’s Who® website at www.marquiswhoswho.com.
# # #
